| Liver carcinoma

Avastin vs Imfinzi

Side-by-side clinical, coverage, and cost comparison for liver carcinoma.

Deep comparison between: Avastin vs Imfinzi with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsImfinzi has a higher rate of injection site reactions vs Avastin based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Imfinzi but not Avastin, including UnitedHealthcare

Category

Avastin

Imfinzi

At A Glance

RouteIV infusion

FrequencyEvery 2-3 weeks

ClassVEGF inhibitor

RouteIV infusion

FrequencyEvery 2 to 4 weeks

ClassPD-L1 antagonist

Indications

Metastasis from malignant neoplasm of colon and/or rectum
Non-Small Cell Lung Carcinoma
Glioblastoma
Renal Cell Carcinoma
Cervix carcinoma
Malignant neoplasm of ovary
Fallopian Tube Carcinoma
Primary Peritoneal Cancer
Liver carcinoma

Non-Small Cell Lung Carcinoma
Small cell carcinoma of lung
Biliary Tract Cancer
Liver carcinoma
Endometrial Carcinoma
Carcinoma of bladder
Stomach Carcinoma
Gastroesophageal junction cancer

Dosing

Metastasis from malignant neoplasm of colon and/or rectum 5 mg/kg IV every 2 weeks with bolus-IFL, or 10 mg/kg IV every 2 weeks with FOLFOX4; for 2nd-line after a bevacizumab product-containing regimen: 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy.

Non-Small Cell Lung Carcinoma 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel.

Glioblastoma 10 mg/kg IV every 2 weeks.

Renal Cell Carcinoma 10 mg/kg IV every 2 weeks with interferon alfa.

Cervix carcinoma 15 mg/kg IV every 3 weeks with paclitaxel and cisplatin, or paclitaxel and topotecan.

Malignant neoplasm of ovary, Fallopian Tube Carcinoma, Primary Peritoneal Cancer Stage III/IV following initial surgical resection: 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel for up to 6 cycles, then 15 mg/kg every 3 weeks as single agent for up to 22 total cycles. Platinum-resistant recurrent: 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks with paclitaxel, pegylated liposomal doxorubicin, or topotecan. Platinum-sensitive recurrent: 15 mg/kg every 3 weeks with carboplatin and paclitaxel or carboplatin and gemcitabine for 6-10 cycles, then 15 mg/kg every 3 weeks as single agent.

Liver carcinoma 15 mg/kg IV every 3 weeks administered after atezolizumab 1,200 mg IV on the same day.

Resectable NSCLC Neoadjuvant: 1,500 mg IV every 3 weeks in combination with chemotherapy for up to 4 cycles prior to surgery (or 20 mg/kg if weight <30 kg). Adjuvant: 1,500 mg IV every 4 weeks as a single agent for up to 12 cycles after surgery (or 20 mg/kg if weight <30 kg).

Unresectable Stage III NSCLC 1,500 mg IV every 4 weeks or 10 mg/kg every 2 weeks as a single agent until disease progression or unacceptable toxicity (maximum 12 months) (or 10 mg/kg every 2 weeks if weight <30 kg).

Metastatic NSCLC 1,500 mg IV in combination with tremelimumab-actl 75 mg and platinum-based chemotherapy every 3 weeks for 4 cycles, then 1,500 mg every 4 weeks as a single agent with pemetrexed maintenance for non-squamous (or 20 mg/kg and 1 mg/kg tremelimumab-actl if weight <30 kg).

Limited Stage SCLC 1,500 mg IV every 4 weeks as a single agent until disease progression or unacceptable toxicity (maximum 24 months) (or 20 mg/kg if weight <30 kg).

Extensive Stage SCLC 1,500 mg IV every 3 weeks in combination with etoposide and carboplatin or cisplatin for 4 cycles, then 1,500 mg every 4 weeks as a single agent until disease progression (or 20 mg/kg if weight <30 kg).

Biliary Tract Cancer 1,500 mg IV every 3 weeks in combination with gemcitabine and cisplatin for up to 8 cycles, then 1,500 mg every 4 weeks as a single agent until disease progression (or 20 mg/kg if weight <30 kg).

Unresectable Hepatocellular Carcinoma 1,500 mg IV in combination with a single dose of tremelimumab-actl 300 mg at Cycle 1/Day 1, followed by 1,500 mg every 4 weeks as a single agent until disease progression (or 20 mg/kg and 4 mg/kg tremelimumab-actl if weight <30 kg).

dMMR Endometrial Carcinoma 1,120 mg IV in combination with carboplatin and paclitaxel every 3 weeks for 6 cycles, followed by 1,500 mg every 4 weeks as a single agent until disease progression (or 15 mg/kg followed by 20 mg/kg if weight <30 kg).

Muscle Invasive Bladder Cancer Neoadjuvant: 1,500 mg IV in combination with gemcitabine and cisplatin every 3 weeks for 4 cycles prior to surgery (or 20 mg/kg if weight <30 kg). Adjuvant: 1,500 mg IV every 4 weeks as a single agent for up to 8 cycles after surgery (or 20 mg/kg if weight <30 kg).

Resectable Gastric/Gastroesophageal Junction Adenocarcinoma Neoadjuvant: 1,500 mg IV every 4 weeks with FLOT for up to 2 cycles prior to surgery (or 20 mg/kg if weight <30 kg). Adjuvant: 1,500 mg IV every 4 weeks with FLOT for up to 2 cycles, followed by 1,500 mg as a single agent every 4 weeks for up to 10 cycles (or 20 mg/kg if weight <30 kg).

Contraindications

—

Drug Interactions

232View drug interactions

203View drug interactions

Adverse Reactions

Most common (>10%) Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis.

Serious Gastrointestinal perforations and fistulae, wound healing complications, hemorrhage, arterial thromboembolic events, venous thromboembolic events, hypertension, posterior reversible encephalopathy syndrome, renal injury and proteinuria, infusion-related reactions, ovarian failure, congestive heart failure.

Postmarketing Polyserositis, pulmonary hypertension, mesenteric venous occlusion, gastrointestinal ulcer, intestinal necrosis, anastomotic ulceration, pancytopenia, gallbladder perforation, osteonecrosis of the jaw, renal thrombotic microangiopathy, nasal septum perforation, arterial aneurysms, dissections, and rupture.

Most common (>=10%) Nausea, fatigue, cough, pneumonitis, rash, diarrhea, decreased appetite, musculoskeletal pain, constipation, dyspnea, upper respiratory tract infections, pyrexia, pruritus, headache, vomiting, abdominal pain, hypothyroidism, peripheral neuropathy, alopecia, insomnia

Serious Pneumonitis, pneumonia, hepatitis, colitis, myocarditis, nephritis, endocrinopathies, infusion-related reactions, exfoliative dermatologic conditions

Postmarketing Not specified in label

Pharmacology

Bevacizumab is a VEGF inhibitor that binds VEGF and prevents its interaction with receptors Flt-1 and KDR on endothelial cells, inhibiting endothelial cell proliferation and new blood vessel formation, thereby reducing tumor microvascular growth and metastatic disease progression.

Durvalumab is a human IgG1 kappa monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, releasing the inhibition of immune responses without inducing antibody-dependent cell-mediated cytotoxicity.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Avastin